Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Elizabeth Boutin McGrath"'
Publikováno v:
Journal of Clinical Oncology. 40:230-230
230 Background: Survivorship care often occurs within a single visit at the end of treatment to discuss a treatment summary and/or survivorship care plan with a patient. With increased understanding of both immediate and long-term effects of cancer a
Publikováno v:
Journal of the Advanced Practitioner in Oncology
Research has demonstrated that cancer survivors who receive a survivorship care plan (SCP) have better coordinated follow-up care, higher overall satisfaction, and report significantly fewer posttreatment emotional concerns. The Commission on Cancer,
Autor:
Elizabeth Boutin McGrath, Gabriel A. Brooks, Jason Edward Faris, Gregory J. Tsongalis, Wahab A. Khan, Sarah K. Walsh, Kathryn Cunningham Hourdequin, Gregory H. Ripple, Mohammad Waleed, Manik Amin, Philip R. Benoit, Kara Beloin
Publikováno v:
Journal of Clinical Oncology. 39:216-216
216 Background: Dihyropyrimidine dehydrogenase (DPD) deficiency is present in 3-5% of patients, and is associated with substantially increased risk of severe and/or fatal toxicity during standard-dose FP chemotherapy. Genotyping of pathogenic DPYD va
Autor:
Samantha Rossi, Judi Gentes, Jean Coffey, Ashley Riley, Stacey Aldrich, Sara Smith, Molly Bennett, Carissa Morton, John M. Hill, Elizabeth Boutin McGrath, Lisa Wesinger, Jennifer Holl, Ashley Prokopik
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S473
Autor:
Stuart R. Gordon, Spencer L. James, Kathryn Cunningham Hourdequin, Kerrington D. Smith, Bassem I. Zaki, Richard J. Barth, Joseph J. Shatzel, J. Marc Pipas, Michael J. Tsapakos, Timothy B. Gardner, Kabir Mody, John E. Sutton, Elizabeth Boutin McGrath, Thomas A. Colacchio, Arief A. Suriawinata, Rebecca Wang, Gregory H. Ripple, Gregory J. Tsongalis
Publikováno v:
Journal of Clinical Oncology. 32:e15189-e15189
e15189 Background: The role of neoadjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) remains unclear, but has demonstrated benefit in many studies. CA 19-9 is a commonly used tumor marker ...
Autor:
Gregory J. Tsongalis, Joseph J. Shatzel, Stuart R. Gordon, Parambir S. Dulai, Kabir Mody, Kerrington D. Smith, John E. Sutton, Michael J. Tsapakos, Gregory H. Ripple, Spencer L. James, Kathryn Cunningham Hourdequin, Timothy B. Gardner, Bassem I. Zaki, Rebecca Wang, J. Marc Pipas, Richard J. Barth, Elizabeth Boutin McGrath, Thomas A. Colacchio, Arief A. Suriawinata
Publikováno v:
Journal of Clinical Oncology. 32:e15262-e15262
e15262 Background: Patients receiving gemcitabine-based neoadjuvant chemoradiotherapy for non-metastatic pancreatic cancer often have difficulty tolerating full treatment courses. Providers are thu...